Literature DB >> 7492112

Activity of penciclovir against Epstein-Barr virus.

T H Bacon1, M R Boyd.   

Abstract

Penciclovir inhibited the productive replication cycle of Epstein-Barr virus (EBV) in assays measuring infectious virus production, viral antigen expression, and viral DNA synthesis. In the test measuring inhibition of EBV DNA synthesis, 50% effective concentrations of penciclovir and acyclovir were 2.3 +/- 0.8 and 2.2 +/- 0.6 micrograms/ml, respectively. The 50% cell growth inhibitory concentration of penciclovir was > 100 micrograms/ml for both P3HR-1 and Raji cells. Penciclovir is a selective inhibitor of EBV in cell culture.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7492112      PMCID： PMC162789          DOI： 10.1128/AAC.39.7.1599

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA).

Authors:  J V PULVERTAFT
Journal:  Lancet       Date:  1964-02-01       Impact factor: 79.321

2.  Regression of oral hairy leukoplakia after orally administered acyclovir therapy.

Authors:  L Resnick; J S Herbst; D V Ablashi; S Atherton; B Frank; L Rosen; S N Horwitz
Journal:  JAMA       Date:  1988-01-15       Impact factor: 56.272

3.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

Authors:  G Klein; B Giovanella; A Westman; J S Stehlin; D Mumford
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

4.  Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems.

Authors:  E Littler; J R Arrand
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

5.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

6.  Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells.

Authors:  R A Hodge; R M Perkins
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

7.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

Authors:  D L Earnshaw; T H Bacon; S J Darlison; K Edmonds; R M Perkins; R A Vere Hodge
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis.

Authors:  C van der Horst; J Joncas; G Ahronheim; N Gustafson; G Stein; M Gurwith; G Fleisher; J Sullivan; J Sixbey; S Roland
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

9.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

10.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103
View more
  9 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  A rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus.

Authors:  Mark N Prichard; Shannon L Daily; Geraldine M Jefferson; Amie L Perry; Earl R Kern
Journal:  J Virol Methods       Date:  2007-05-30       Impact factor: 2.014

4.  Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Authors:  Natacha Coen; Sophie Duraffour; Dimitri Topalis; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

5.  In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents.

Authors:  J Neyts; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography.

Authors:  Dennis R Weller; Henry H Balfour; Heather E Vezina
Journal:  Biomed Chromatogr       Date:  2009-08       Impact factor: 1.902

Review 7.  Antiviral drugs for viruses other than human immunodeficiency virus.

Authors:  Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

Review 8.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

9.  Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies.

Authors:  M D de Jong; C A Boucher; D A Cooper; G J Galasso; B Gazzard; J M Lange; J S Montaner; D D Richman; H C Thomas
Journal:  Antiviral Res       Date:  1997-07       Impact factor: 5.970
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.